NGFR
ENSG00000064300
Target class
Membrane receptor
Chromosome
17
- Chemical probe available
- No
- Target name
- NGFR
- Gene name
- Nerve growth factor receptor
- Gene symbol
- NGFR
- Protein name
- Tumor necrosis factor receptor superfamily member 16 (Gp80-LNGFR) (Low affinity neurotrophin receptor p75NTR) (Low-affinity nerve growth factor receptor) (NGF receptor) (Low-affinity nerve growth factor receptor p75NGFR) (Low-affinity nerve growth factor receptor p75NGR) (p75 ICD) (CD antigen CD271)
- TNFRSF16
- CD271
- p75NTR
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Tumor necrosis factor receptor superfamily|MicroRNA protein coding host genes
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 50
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 374.41
- Tissue specificity (Gini)
- 0.593
- Tissue specificity (tau)
- 0.952
- KEGG gene identifiers
- hsa:4804
- Protein interaction confidence
- 0.848066
- Protein interaction partners
- 91
- R-HSA-193634
- R-HSA-193648
- R-HSA-193670
- R-HSA-193681
- R-HSA-193692
- R-HSA-205017
- R-HSA-205025
- R-HSA-205043
- R-HSA-209543
- R-HSA-209560
- R-HSA-209563
- End position
- 49515008
- Start position
- 49495293
- Chromosome
- 17
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein . Cytoplasm . Perikaryon . Cell projection, growth cone . Cell projection, dendritic spine .
- Plasma membrane
- PubMed 3022937
- PubMed 22566094
- Tissue specificity (tau)
- 0.951935
- Expression inequality (Gini)
- 0.592723
Expression in transcripts per million
- Nerve - Tibial
- 374.41
- Thyroid
- 63.98
- Adipose - Visceral (Omentum)
- 54.82
- Artery - Coronary
- 41.68
- Breast - Mammary Tissue
- 39.6
Expression in transcripts per million
- Nerve - Tibial374.41
- Thyroid63.98
- Adipose - Visceral (Omentum)54.82
- Artery - Coronary41.68
- Breast - Mammary Tissue39.6
- Heart - Atrial Appendage37.75
- Minor Salivary Gland37
- Prostate36.58
- Spleen36.55
- Cervix - Endocervix35.89
- Colon - Sigmoid31.49
- Adrenal Gland29.54
- Adipose - Subcutaneous29.2
- Artery - Tibial29.16
- Brain - Spinal cord (cervical c-1)28.78
- Fallopian Tube28.53
- Esophagus - Gastroesophageal Junction27.2
- Skin - Sun Exposed (Lower leg)26.97
- Esophagus - Muscularis25.68
- Skin - Not Sun Exposed (Suprapubic)23.73
- Artery - Aorta22.41
- Cervix - Ectocervix20.91
- Vagina20.21
- Pituitary19.51
- Bladder19.47
And 29 more, listed on the interactive page.
- GO:0007266
- GO:0030336
- GO:0051402
- GO:0097191
- GO:1900182
- GO:1902895
- GO:1903588
- GO:1904646
- GO:2000353
- GO:0005576
- GO:0005654
- GO:0005737
- GO:0005768
- GO:0005829
- GO:0005886
- GO:0001540
- GO:0004888
- GO:0005035
- GO:0005515
- GO:0005516
- GO:0015026
- GO:0031625
- GO:0038023
Related records
Trials (22)
- A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery
- A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.
- An 8-week Follow-up to Evaluate the Renewal of Corneal Nerves Structure and Function in Patients With Neurotrophic Keratopathy Treated With Recombinant Human Nerve Growth Factor (rhNGF) Eyedrops
- An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
- Corneal Nerves After Treatment With Cenegermin
- Corneal Neurotization vs. Cenergermin for Neurotrophic Keratitis: A Pilot Study
- Cortical Neuroplasticity by Muscle Pain of Pain-induced Plasticity
- DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
- DOMPE -MT Neurotrophic Keratitis
- Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
- Nerve Growth Factor for the Treatment of Cornea Disease
- NGF Treatment for Patients With Neuropathic Corneal Pain
- OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate
- Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis
- Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye
- Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)
- Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis
- Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease
- Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma
- Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers